Patient and Healthcare Provider Resource

Patient and Healthcare Providers Resource

OralChemoEdSheets.com, Patient + Healthcare Providers Resource

OralChemoEdSheets.com, the Patient and Healthcare Providers Resource

Generic

Acalabrutinib

()

Brand

CALQUENCE®

()

Acalabrutinib (CALQUENCE®) is a novel experimental anti-cancer drug and a 2nd generation Bruton's tyrosine kinase inhibitor developed by Acerta Pharma. It is more potent and selective than ibrutinib, the first-in-class BTK inhibitor.

 
Our Medication Sheet

This sheet is coming soon. check back later to download it as an Adobe PDF.

 

Our Foundation Sponsors

Our Sustaining Sponsors